Evidence map›Paper›PMID 38005931›Full record

ArticleViruses2023

Integrase Defective Lentiviral Vector Promoter Impacts Transgene Expression in Target Cells and Magnitude of Vector-Induced Immune Responses.

Sneha Mahesh, Jenny Li, Tatianna Travieso, Danai Psaradelli, Donatella Negri, Mary Klotman, Andrea Cara, Maria Blasi

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Sneha MaheshDepartment of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
Jenny LiDepartment of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
Tatianna TraviesoDepartment of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
Danai PsaradelliDepartment of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
Donatella NegriDepartment of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
Mary KlotmanDepartment of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
Andrea CaraDepartment of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
Maria BlasiDepartment of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-7091-0312
Duke University · US

Funding

Targeting the HIV-1 reservoir with a combination of an IDLV-SIVGag therapeutic vaccine and Fc-engineered bnAbsR56AI150359 · NIAID · DUKE UNIVERSITY · PI BLASI, MARIA · 2020 to 2020
$760k
NIAID NIH HHS R56 AI150359
6 · The paper itself

Abstract

Integrase defective lentiviral vectors (IDLVs) are a promising vaccine delivery platform given their ability to induce high magnitude and durable antigen-specific immune responses. IDLVs based on the simian immunodeficiency virus (SIV) are significantly more efficient at transducing human and simian dendritic cells (DCs) compared to HIV-based vectors, resulting in a higher expansion of antigen-specific CD8+ T cells. Additionally, IDLV persistence and continuous antigen expression in muscle cells at the injection site contributes to the durability of the vaccine-induced immune responses. Here, to further optimize transgene expression levels in both DCs and muscle cells, we generated ten novel lentiviral vectors (LVs) expressing green fluorescent protein (GFP) under different hybrid promoters. Our data show that three of the tested hybrid promoters resulted in the highest transgene expression levels in mouse DCs, monkey DCs and monkey muscle cells. We then used the three LVs with the highest in vitro transgene expression levels to immunize BALB/c mice and observed high magnitude T cell responses at 3 months post-prime. Our study demonstrates that the choice of the vector promoter influences antigen expression levels in target cells and the ensuing magnitude of T cell responses in vivo.

Indexed as

IntegrasesVaccinesAnimalsGenetic VectorsHaplorhiniHumansImmunityLentivirusMiceTransgenesIntegrasesVaccinesantigen expressiondendritic cellsimmune responseslentiviral vectorsmuscle cellsvector promoter

Identifiers

PMID38005931
PMCPMC10674321
OpenAlexW4388683999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.